The Red Journal editors are delighted to announce that in 2020 we will have a special edition looking at the new science connecting radiation therapy and the immune response. We feel that this subject is very timely and of critical importance for the future of our specialty, and are calling for original scientific studies, clinical trials, review articles, and opinion pieces on its many aspects….
Register for ASTRO’s radiopharmaceutical webinar series.
ASTRO Awards two grants of up to $10,000 each year to patient support organizations in the cities that host the Annual Meeting. Learn more and…
The POP-RT phase III randomized trial showed improved biochemical failure-free survival and metastasis-free survival with whole pelvic radiotherapy (WPRT) versus prostate-only radiotherapy (PORT) for high/very…
: This guideline provides evidence-based recommendations on appropriate indications and techniques for partial breast irradiation (PBI) for patients with early-stage invasive breast cancer and ductal…
The 2024 ASTRO Annual Meeting will be held at the Walter E. Washington Convention Center, Washington, DC, and virtually September 29-October 2, 2024.
Alliance A021501 is the first randomized trial to evaluate stereotactic body radiation therapy (SBRT) for borderline resectable pancreatic ductal adenocarcinoma (PDAC) after neoadjuvant chemotherapy. In…
ASTRO holds annual elections for its Board of Directors.
All members interested in applying for ASTRO Fellow designation should fill out this application.
Background and purpose: The dose deposited outside of the treatment field during external photon beam radiotherapy treatment, also known as out-of-field dose, is the subject…
ASTRO-BCRF travel award are offered to trainees attending the 2024 ASTRO Annual Meeting in Washington, DC, September 29-October 2, 2024.
